Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH5030 in HER2+ Biliary Tract or Colorectal Cancer
NCT06434597Phase 2Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sph5030 in biliary tract cancer (BTC), colorectal cancer (CRC), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jul 2024; status: recruiting.
02
Drugs
sph5030
03
Conditions
biliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06434597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434597.